For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
Blog
This week in health care policy: October 31-November 6, 2026
Drug pricing and PBMs Medicare’s second round of negotiated prices starts in two months. On January 1, negotiated prices for…
Blog
This week in health care policy: October 24-30, 2026
FDA and innovation FDA and CMS move on personalized gene therapies. The FDA released draft guidance that lets developers of…
Blog
Market-oriented reforms that can save Medicare $100 billion
Since 1970, Medicare spending has grown from 0.7 percent of GDP to 4.0 percent of GDP, and it is projected to grow even further.
Search Posts
National Review
Evicting the Constitution
Few government actions have been more emblematic of bureaucratic overreach than the Centers for Disease Control and Prevention’s nationwide eviction moratorium. After multiple successful…
New York Post
Hasty About-Face Distorts Delta Force
The CDC now urges public indoor masking after a worrisome study on the Delta variant — undermining the vaccine effort. We finally know what…
City Journal
The CDC’s Slender Reed
The Centers for Disease Control and Prevention (CDC) has reversed its guidance from two months ago and now recommends that fully vaccinated…
Blog
Tobacco Control’s Latest Self-Fulfilling Prophecy
If you want to make something irresistible to teenagers, portray it as a forbidden fruit. That is what has happened in the U.S. with…
National Review
The True Meaning of ‘Misinformation’
Last week Senators Amy Klobuchar (D., Minn.) and Ben Ray Luján (D., N.M.) introduced a bill designed to suppress dangerous misinformation about COVID-19 vaccines. Like…
National Review
A Defeat for Dr. Leviathan
A recent ruling by the D.C. Circuit Court of Appeals in a seemingly obscure case has important implications for limits on the Food and Drug…